Unknown

Dataset Information

0

Clinical Trial of the Anti-PD-L1 Antibody BMS-936559 in HIV-1 Infected Participants on Suppressive Antiretroviral Therapy.


ABSTRACT: Background:Reversing immune exhaustion with an anti-PD-L1 antibody may improve human immunodeficiency virus type 1 (HIV-1)-specific immunity and increase clearance of HIV-1-expressing cells. Methods:We conducted a phase I, randomized, double-blind, placebo-controlled, dose-escalating study of BMS-936559, including HIV-1-infected adults aged >18 to <70 years on suppressive antiretroviral therapy with CD4+ counts >350 cells/?L and detectable plasma HIV-1 RNA by single-copy assay. Data on single infusions of BMS-936559 (0.3 mg/kg) versus placebo are described. The primary outcomes were safety defined as any grade 3 or greater or immune-related adverse event (AE) and the change in HIV-1 Gag-specific CD8+ T cell responses from baseline to day 28 after infusion. Results:Eight men enrolled: 6 received 0.3 mg/kg of BMS-936559, and 2 received placebo infusions. There were no BMS-936559-related grade 3 or greater AEs. In 1 participant, asymptomatic hypophysitis (a protocol-defined immune-related AE) was identified 266 days after BMS-936559 infusion; it resolved over time. The mean percentage of HIV-1 Gag-specific CD8+ T cells expressing interferon ? increased from baseline (0.09%) through day 28 (0.20%; P = .14), driven by substantial increases in 2 participants who received BMS-936559. Conclusions:In this first evaluation of an immunologic checkpoint inhibitor in healthy HIV-1-infected persons, single low-dose BMS-936559 infusions appeared to enhance HIV-1-specific immunity in a subset of participants. Clinical Trials Registration:NCT02028403.

SUBMITTER: Gay CL 

PROVIDER: S-EPMC5790148 | biostudies-literature | 2017 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications

Clinical Trial of the Anti-PD-L1 Antibody BMS-936559 in HIV-1 Infected Participants on Suppressive Antiretroviral Therapy.

Gay Cynthia L CL   Bosch Ronald J RJ   Ritz Justin J   Hataye Jason M JM   Aga Evgenia E   Tressler Randall L RL   Mason Stephen W SW   Hwang Carey K CK   Grasela Dennis M DM   Ray Neelanjana N   Cyktor Josh C JC   Coffin John M JM   Acosta Edward P EP   Koup Richard A RA   Mellors John W JW   Eron Joseph J JJ  

The Journal of infectious diseases 20170601 11


<h4>Background</h4>Reversing immune exhaustion with an anti-PD-L1 antibody may improve human immunodeficiency virus type 1 (HIV-1)-specific immunity and increase clearance of HIV-1-expressing cells.<h4>Methods</h4>We conducted a phase I, randomized, double-blind, placebo-controlled, dose-escalating study of BMS-936559, including HIV-1-infected adults aged >18 to <70 years on suppressive antiretroviral therapy with CD4+ counts >350 cells/μL and detectable plasma HIV-1 RNA by single-copy assay. Da  ...[more]

Similar Datasets

| S-EPMC5853506 | biostudies-literature
| S-EPMC6605872 | biostudies-literature
| S-EPMC7445348 | biostudies-literature
| S-EPMC6834253 | biostudies-literature
| S-EPMC5685743 | biostudies-literature
| S-EPMC7253691 | biostudies-literature
| S-EPMC4231123 | biostudies-literature
| S-EPMC8717122 | biostudies-literature
| S-EPMC5552229 | biostudies-literature
| S-EPMC8553560 | biostudies-literature